Aug 2026· Cell Reports Medicine· Vol 7, pp. 103008· 0 citations· 104 references
Medicine
TL;DR
De deleting Reg-1 has cell- and non-cell-autonomous benefits, nominating Reg-1 KO B7-H3-CAR T cells as a promising cell product for early-phase clinical testing in patients with solid tumors.
Abstract
Summary The microenvironment in solid tumors represents an immunosuppressive therapeutic barrier to CAR T cell therapy, and it is currently unknown whether it can be reshaped by the deletion of negative regulators in CAR T cells. To address this knowledge gap, we evaluated the intrinsic and extrinsic effects of deleting the negative regulator Regnase-1 (Reg-1) in B7-H3-CAR T cells for the immunotherapy of osteosarcoma. Reg-1 knockout (KO) improved the antitumor activity of human and murine B7-H3-CAR T cells in vivo. In immune-competent models, Reg-1 KO also endowed murine B7-H3-CAR T cells with the ability to create a proinflammatory landscape characterized by an influx of interferon gamma (IFN-γ)-producing endogenous T cells and natural killer (NK) cells and a reduction of inhibitory myeloid cells, including M2-like macrophages. Thus, deleting Reg-1 has cell- and non-cell-autonomous benefits, nominating Reg-1 KO B7-H3-CAR T cells as a promising cell product for early-phase clinical testing in patients with solid tumors.
In the SKOV3-A2 solid tumor xenograft model, WT1-CAR-Nb T cells mediated superior tumor growth control and significantly prolonged overall survival, which was closely correlated with enhanced intratumoral T cell infiltration and persistent in vivo expansion of engineered T cells.
Wan-Jun He, Kai Cui, Yi-Wei Zeng et al.· Journal of Translational Med...· 0 citations
Abstract Background Targeting the high-affinity interleukin-2 receptor (IL-2R) on CD8+ T effector cells elicits potent antitumor responses that are augmented when co-administered with programmed cell death protein 1 (PD-1) blockade. Methods Using the mouse IL-2/CD25 fusion protein (mIL-2/CD25) at a high dose (HD) and a...
Kathryn M. Laporte, Janika Põder, D. Ivanova et al.· Journal for ImmunoTherapy of...· 0 citations
Findings establish ATRA as a modulator of CD8⁺ T-cell exhaustion through the induction of WNT/β-catenin-dependent TCF-1βBD expression, suggesting that ATRA has therapeutic potential for overcoming resistance to ICB in glioma.
In Kang, Yumin Kim, Byeonguk Kang et al.· Signal Transduction and Targ...· 0 citations
Chimeric antigen receptor (CAR)-T cell exhaustion constitutes a critical barrier to sustained antitumor efficacy. Through transcriptomic analysis of CAR-T cells from patients with lymphoma, we identified the histone variant macroH2A2 (H2AFY2) as a critical regulator of T cell exhaustion-a finding consistently observed...
C. Li, Qian Wang, Qi-Tai Zhao et al.· Cancer immunology research· 0 citations
It is suggested that the SHMT2–lactate–CAF axis contributes to the metabolic–stromal regulation of T-cell exclusion and may represent a potential therapeutic target for improving the response of immune-excluded HNSCC to PD-1 blockade.
He-Lei Yan, Lu Wang, Zhen Li et al.· Cell Death & Disease· 0 citations